title: Assessing the relative efficacy of new drugs: an emerging opportunity.
abstract: The increasing availability of individual-level data from clinical trials could allow the relative efficacy of new drugs to be assessed in a robust, cost-effective and timely way.
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Eichler
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Thomson
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Irmgard
authors.initials: I
authors.lastname: Eichler
authors.affiliation: Division of Pharmacoepidemiology, Department of Medicine, Brigham and Womens Hospital and Harvard Medical School, 1 Brigham Circle, Boston, Massachusetts 02120, USA.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Schneeweiss
mesh_terms: D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000191:economics; D003362:Cost-Benefit Analysis / Q000639:trends*; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000191:economics / Q000639:trends; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational